That’s an interesting question. You’ll typically find PSA kinetics (velocity, doubling time) in surveillance but not PSAD, and I suspect it is for a number of reasons (a main one being the feasibility of pairing an accurate volume with PSA - remember, most patients are screened and followed by their primary doctors). Also, there are some issues with the inflexible cutoff values (per my understanding) that complicate clinical decision making.
Should there be more use of PSAD in the protocol?
That’s an interesting question. You’ll typically find PSA kinetics (velocity, doubling time) in surveillance but not PSAD, and I suspect it is for a number of reasons (a main one being the feasibility of pairing an accurate volume with PSA - remember, most patients are screened and followed by their primary doctors). Also, there are some issues with the inflexible cutoff values (per my understanding) that complicate clinical decision making.